GI Gains: Lupin Targets $184M Market with New FDA-Approved Tablets

Unknown Apr 02, 2026 1,050 Views

Lupin Ltd has begun marketing its Prucalopride Tablets 1 mg and 2 mg in the United States following approval of its Abbreviated New Drug Application (ANDA) from the FDA. The drug is a generic bioequivalent of Takeda's Motegrity® and is approved to be used for adults with Chronic Idiopathi...